P292 Inflammatory bowel disease and their implications in Roma ethnicity: A preliminary study

2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S298-S299
Author(s):  
B Castro ◽  
M J García García ◽  
M Pascual ◽  
J L Fernández-Forcelledo ◽  
J Crespo ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Ethnic Group ◽  
Surgical Procedures ◽  
Bowel Disease ◽  
Clinical Characteristics ◽  
Hospital Admissions ◽  
Aggressive Disease ◽  
Significant Difference ◽  
Caucasian Patients ◽  
Inflammatory Bowel

Abstract Background The pathogenesis of inflammatory bowel disease (IBD) is multifactorial and many factors have been involved such as genetic or environmental elements. The characteristics of IBD in different ethnic groups have been investigated to clarify the North-South gradient. We considered that Roma patients seem to have a more aggressive disease than Caucasian patients but no data to support this feeling is published. For this reason, the aim of our study is to analyse clinical characteristics of our cohort of IBD patients comparing Roma and Caucasian ethnicity Methods A retrospective cohort study was realised in both IBD Units to compare Roma and Caucasian groups. IBD patients were identified in the outpatient clinic. Demographical, clinical characteristics, pharmaceutical requirements and surgeries were collected. This group was matched by age, gender, disease and location of IBD with Caucasian patients. Results 24 Roma patients were identified in our cohort. The prevalence of Gypsy ethnic group in our cohort was 1.66%. A percentage of 41.67% were men (n = 10) meanwhile 58.33% (n = 14) were women. The average age of the patients of our cohort was 43.77 years (SD 12.82). Crohn’s disease (CD) was observed in 62.5% (n = 15), ulcerative colitis (UC) in 29.19% (n = 7) and Unclassified IBD in 8.33% (n = 2). A statistic significant difference in family history was observed in the group of Roma patients (50%, n = 12 vs. 8.34%, n = 2) (p =0.001). Regarding to therapy, the Roma group required biological treatment in 58,32% (n = 14) compare to a percentage of 25% (n = 6) (p = 0.019) in the Caucasian group. We also found more hospital admissions (5.18 (SD 4,33) vs. 2,5 (SD 1,93) (p = 0,04)) and surgical procedures (41.66%, n = 10 vs. 12.5%, n = 3) (p = 0,023). Conclusion In our cohort, the Roma IBD patients showed more familial aggregation than the Caucasian group. An aggressive disease was also found in Roma patients and the subsequent increase in biological therapy, hospital admissions and surgical procedures to control the disease. Future studies should be performing to investigate genetic or environmental factors associated with this ethnic group.

scholarly journals Risk and characteristics of tuberculosis after anti-tumor necrosis factor therapy for inflammatory bowel disease: a hospital-based cohort study from Korea

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Jae Yong Lee ◽  
Kyunghwan Oh ◽  
Hee Seung Hong ◽  
Kyuwon Kim ◽  
Seung Wook Hong ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Tumor Necrosis Factor ◽  
Incidence Rate ◽  
Bowel Disease ◽  
Clinical Characteristics ◽  
Tumor Necrosis ◽  
Medical Center ◽  
Significant Difference ◽  
Inflammatory Bowel ◽  
Necrosis Factor

Abstract Background Anti-tumor necrosis factor (TNF) treatment for inflammatory bowel disease (IBD) increases the risk of tuberculosis (TB) infection. In the present study, we analyzed the clinical characteristics and risks of TB in Korean patients with IBD who received anti-TNF treatment. Methods The study included patients with IBD who were treated using anti-TNF agents between January 2001 and June 2018 at the Asan Medical Center. Overall, 1434 patients with ulcerative colitis or Crohn’s disease were enrolled. We calculated the incidence of active TB infection after anti-TNF treatment and compared the clinical characteristics of the TB group with those of the non-TB group. Results Twenty-one patients (1.46%) developed active TB infection, and the incidence rate of active TB was 366.73 per 100,000 person-years. In total, 198 patients (14.9%) were positive for latent tuberculosis infection (LTBI), of whom only eight (4%) did not complete LTBI treatment. The age at which the anti-TNF therapy was started was significantly higher in the TB group than in the non-TB group (HR 1.041, 95% CI 1.014–1.069, p = 0.002), and as age increased, so did the incidence rate of active TB infection (linearity p < 0.001). There was no significant difference in the incidence rate of LTBI between the TB and non-TB groups (HR 0.896, 95% CI 0.262–3.066, p = 0.862). Conclusions In patients with IBD, the incidence rate of TB increased with age at anti-TNF therapy initiation. Active treatment of LTBI may lower the incidence of TB in patients with IBD who are to undergo anti-TNF therapy.

scholarly journals SAT0462 ASSESSMENT OF BONE MINERAL DENSITY IN INFLAMMATORY BOWEL DISEASE

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1188.1-1188
Author(s):  
C. Daldoul ◽  
N. El Amri ◽  
K. Baccouche ◽  
H. Zeglaoui ◽  
E. Bouajina
Keyword(s):  
Bone Mineral Density ◽  
Inflammatory Bowel Disease ◽  
Bone Mineral ◽  
Bowel Disease ◽  
Mineral Density ◽  
Femoral Site ◽  
Significant Difference ◽  
History Of ◽  
Inflammatory Bowel ◽  
The Mean

Background:Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), is considered as a risk factor of low bone mineral density (BMD). In fact, the prevalence of osteoporosis ranges from 17% to 41% in IBD patients. The possible contributing factors may include malabsorption, glucocorticoid treatment and coexisting comorbiditiesObjectives:The purpose of our work was to determine the frequency and the determinants of osteoporosis in patients with IBD and to assess whether there is a difference in BMD status between UC and CD.Methods:This is a retrospective study, over a period of 5 years (from January 2014 to December 2018) and including patients followed for IBD who had a measurement of BMD by DEXA. Clinical, anthropometric and densitometric data (BMD at the femoral and vertebral site) were recorded. The WHO criteria for the definition of osteoporosis and osteopenia were applied.Results:One hundred and five patients were collected; among them 45 were men and 60 were women. The average age was 45.89 years old. The average body mass index (BMI) was 25.81 kg/m2 [16.44-44.15]. CD and UC were diagnosed in respectively 57.1% and 42.9%. A personal history of fragility fracture was noted in 4.8%. Hypothyroidism was associated in one case. Early menopause was recorded in 7.6%. 46.8% patients were treated with corticosteroids. The mean BMD at the vertebral site was 1.023 g/cm3 [0.569-1.489 g/cm3]. Mean BMD at the femoral site was 0.920g/cm3 [0.553-1.286g / cm3]. The mean T-score at the femoral site and the vertebral site were -1.04 SD and -1.27 SD, respectively. Osteoporosis was found in 25.7% and osteopenia in 37.1%. Osteoporosis among CD and UC patients was found in respectively 63% and 37%. The age of the osteoporotic patients was significantly higher compared to those who were not osteoporotic (52.23 vs 43.67 years, p = 0.01). We found a significantly higher percentage of osteoporosis among men compared to women (35.6% vs 18.3%, p=0.046). The BMI was significantly lower in the osteoporotic patients (23.87 vs 26.48 kg/m2, p=0.035) and we found a significant correlation between BMI and BMD at the femoral site (p=0.01). No increase in the frequency of osteoporosis was noted in patients treated with corticosteroids (27.9% vs 21.6%, p=0.479). Comparing the UC and CD patients, no difference was found in baseline characteristics, use of steroids or history of fracture. No statistically significant difference was found between UC and CD patients for osteoporosis(p=0.478), BMD at the femoral site (p=0.529) and at the vertebral site (p=0.568).Conclusion:Osteoporosis was found in 25.7% of IBD patients without any difference between CD and UC. This decline does not seem to be related to the treatment with corticosteroids but rather to the disease itself. Hence the interest of an early screening of this silent disease.Disclosure of Interests:None declared

scholarly journals A183 TELEHEALTH USE IN RURAL SASKATCHEWAN AND INFLAMMATORY BOWEL DISEASE OUTCOMES

2021 ◽  
Vol 4 (Supplement_1) ◽  
pp. 197-199
Author(s):  
M Patterson ◽  
M Gozdzik ◽  
J Peña-Sánchez ◽  
S Fowler
Keyword(s):  
Health Care ◽  
Inflammatory Bowel Disease ◽  
Health Care Utilization ◽  
Bowel Disease ◽  
Postal Code ◽  
Care Utilization ◽  
Specialist Care ◽  
Disease Characteristics ◽  
Significant Difference ◽  
Inflammatory Bowel

Abstract Background Appropriate management of inflammatory bowel disease (IBD) often requires multiple specialist appointments per year. Living in rural locations may pose a barrier to regular specialist care. Saskatchewan (SK) has a large rural population. Prior to COVID-19, telehealth (TH) in SK was not routinely used for either patient assessment or follow up. Furthermore, TH was exclusively between hospitals and specific TH sites without direct contact using patient’s personal phones. Aims The objective of this study was to assess the differences in demographics, disease characteristics, outcomes, and health care utilization between patients from rural SK with IBD who used TH and those who did not. Methods A retrospective chart review was completed on all rural patients (postal code S0*) with IBD in SK who were followed at the Multidisciplinary IBD Clinic in Saskatoon between January 2018 and February 2020. Patients were classified as using TH if they had ever used it. Information on demographics, disease characteristics, and access to IBD-related health care in the year prior to their last IBD clinic visit or endoscopy was collected. Data was not collected for clinic visits after March 1, 2020 as all outpatient care became remote secondary to the COVID-19 pandemic. Mean, standard deviations, median and interquartile ranges (IQR) were reported. Mann-Witney U and Chi-Square tests were used to determine differences between the groups. Results In total, 288 rural SK IBD patients were included, 30 (10.4%) used TH and 258 (89.6%) did not. Patient demographics were not significantly different between the two groups; although, there was a statistically significant difference in the proportion of ulcerative colitis patients (17% TH vs. 38% non-TH, p=0.02). The percentage of patients with clinical remission was 87% for TH patients and 74% for non-TH patients (p=0.13). There were no significant differences in health care utilization patterns and biochemical markers of disease, including c-reactive protein (CRP) and fecal calprotectin (FCP) (p&gt;0.05). Conclusions Prior to the pandemic, a small percentage of patients with IBD in rural SK ever used TH. A small proportion of UC patients used TH. No significant differences in disease characteristics, outcomes, or health care utilization were identified. Further study is warranted to identify barriers to use of this technology to tailor care to this patient group and improve access to care, especially now as the COVID-19 pandemic has drastically changed the use of virtual care. Funding Agencies None

Clinical Characteristics of Inflammatory Bowel Disease in Turkey

2009 ◽  
Vol 43 (1) ◽  
pp. 51-57 ◽  
Author(s):  
Nurdan Tozun ◽  
Ozlen Atug ◽  
Nese Imeryuz ◽  
Hulya O. Hamzaoglu ◽  
Arzu Tiftikci ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Clinical Characteristics ◽  
Inflammatory Bowel

Sa562 CLINICAL CHARACTERISTICS OF MIGRAINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

2021 ◽  
Vol 160 (6) ◽  
pp. S-552-S-553
Author(s):  
Sean M. Sileno ◽  
Fernando Stancampiano ◽  
Hassan Ghoz ◽  
Mohamed Omer ◽  
Ahmed M. Salih ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Clinical Characteristics ◽  
Inflammatory Bowel

Decreasing Rates of Hospital Admissions for Inflammatory Bowel Disease Between 2000 and 2009

2011 ◽  
Vol 140 (5) ◽  
pp. S-267
Author(s):  
Carlos Taxonera ◽  
Juan L. Mendoza ◽  
Dulce M. Cruz-Santamaría ◽  
Natalia López-Palacios ◽  
Cristina Alba ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Hospital Admissions ◽  
Inflammatory Bowel

Nurse-led early evaluation following corticosteroid prescription in patients with inflammatory bowel disease

2021 ◽  
Vol 3 (12) ◽  
pp. 500-506
Author(s):  
Philip R Harvey ◽  
Jayne Slater ◽  
Akram Algieder ◽  
Judith Jones ◽  
Beth Bates ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Retrospective Cohort ◽  
Hospital Admissions ◽  
Care Centre ◽  
Potential Reduction ◽  
Early Evaluation ◽  
Evaluation Group ◽  
Inflammatory Bowel ◽  
Specialist Nurses

Background: The Toronto consensus for management of ulcerative colitis (UC) recommends early evaluation of UC patients 2 weeks after initiation on corticosteroids. A system for early evaluation of inflammatory bowel disease patients was established by specialist nurses in a secondary care centre. Aim: To compare outcomes following early evaluation to the previous service. Methods: All patients undergoing early evaluation over a 1-year period were prospectively audited and compared to a retrospective cohort of patients receiving prednisolone in the preceding year. Findings: Of 140 patients included, 76 (54.3%) underwent early evaluation. All patients in the early evaluation group received drug education and details of the nurse helpline (17.1% of patients did not already have this). Of patients, 81.6% were prescribed Adcal, and 83.9% were on 5-aminosalicylates. Fewer admissions were observed within 6 months following early evaluation (8.6% vs. 23.4%, p=0.013). Conclusion: Multiple benefits of early evaluation were observed, including a potential reduction in hospital admissions.

scholarly journals MiR-155-Mediated Deregulation of GPER1 Plays an Important Role in the Gender Differences Related to Inflammatory Bowel Disease

2020 ◽  
Vol 2020 ◽  
pp. 1-11
Author(s):  
Xiaojuan Shao ◽  
Jintao Li ◽  
Fumin Xu ◽  
Dongfeng Chen ◽  
Kaijun Liu
Keyword(s):  
Gender Differences ◽  
Inflammatory Bowel Disease ◽  
Estrogen Receptor ◽  
Inflammatory Response ◽  
Proinflammatory Cytokines ◽  
Bowel Disease ◽  
Clinical Characteristics ◽  
Intestinal Flora ◽  
Inflammatory Bowel ◽  
Proinflammatory Activity

Aim. The incidence and clinical manifestations of inflammatory bowel disease (IBD) are thought to have gender differences, which suggests that the estrogen signaling pathway and intestinal flora may play key roles in the pathogenesis of IBD. In IBD, microRNA-155 (miR-155) is upregulated and regulates G protein coupled estrogen receptor (GPER1), which affects the intestinal flora. The objective of this study was to investigate the role of the estrogen receptors and miR-155 in the pathogenesis of IBD. Methods. From July 2018 to July 2019, in the Department of Gastroenterology at Daping Hospital, Army Military Medical University, a total of 50 patients with IBD were included in this study, and 24 healthy examinees were randomly selected as the control group. Colonoscopies were performed, and clinical characteristics and blood samples were collected from all of the subjects. The serum cytokine levels in the patients with IBD and the health donors were detected by ELISA, and the estrogen receptor level measurements for all of the participants were assessed by immunohistochemistry (IHC) and quantitative real-time PCR (qPCR). The miR-155 levels were detected by qPCR in all of the participants, and miR-155−/− mice were used to investigate the mechanism of miR-155 in the pathogenesis of IBD. Results. The clinical characteristics and medications were different for the IBD patients when gender was considered. The male patients produced more proinflammatory cytokines, and while GPER1 expression was downregulated, miR-155 was upregulated in the patients with IBD. MiR-155 showed proinflammatory activity, while GPER1 showed an anti-inflammatory response during the pathogenesis of IBD. The miR-155−/− mice showed improvements in weight loss, survival, rectal bleeding, colon length, and histopathological changes compared with the wild-type mice. Furthermore, the male miR-155−/− mice showed increased inflammation compared to the female miR-155−/− mice in the above aspects. Conclusion. This study presents evidence indicating that miR-155 plays a key role in the pathogenesis of IBD for the different genders. MiR-155 was upregulated and showed proinflammatory activity, whereas GPER1 showed an anti-inflammatory response during the pathogenesis of IBD. The results demonstrated that more proinflammatory cytokines and reduced GPER1 levels were observed in the male IBD patients. Thus, miR-155 was involved in the regulation of GPER1 and induced gender differences in IBD patients. MiR-155 may be a potential marker for IBD-targeted therapy.

Sign in / Sign up

Export Citation Format

Share Document